SCHEMBL13495404

SCHEMBL13495404

CON1C(=O)c2cc3cc4ccccc4cc3cc2C1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.41
TNF P01375 1/20 0.40
DRD2 P14416 1/20 0.37
DRD3 P35462 1/20 0.37
RECQL P46063 1/20 0.37
GAPDH P04406 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
VDR P11473 1/20 0.37
CYP1A2 P05177 2/20 0.36
CYP2A6 P11509 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
NQO1 P15559 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HSP90AA1 P07900 1/20 0.35
GAA P10253 1/20 0.35
KDM4E B2RXH2 2/20 0.35
MAPT P10636 2/20 0.35
HPGD P15428 2/20 0.35
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13495401 0.96 MAOA (0.43) MAOATNFDRD2DRD3RECQL
SCHEMBL30219494 0.79 GAA (0.52) RECQLMEN1KMT2AVDRCYP1A2
SCHEMBL798345 0.79 GAA (0.52) RECQLMEN1KMT2AVDRCYP1A2
SCHEMBL19195513 0.78 CASP3 (0.52) MAOAMEN1KMT2AMAPTHPGD
SCHEMBL13495403 0.76 PDGFRB (0.50) MEN1KMT2ACYP1A2SMN1; SMN2HSP90AA1
SCHEMBL13479727 0.75 CA9 (0.39) TNFHSP90AA1MAPTALDH1A1NPSR1
SCHEMBL10040988 0.74 TDP1 (0.60) RECQLMEN1KMT2ATDP1GAA
SCHEMBL12541822 0.73 POLB (0.54) MEN1KMT2ATDP1GAAKDM4E
SCHEMBL12540909 0.73 ESR1 (0.49) RECQLMEN1KMT2AVDRCYP1A2
SCHEMBL12552816 0.73 CASP3 (0.56) MAOAMEN1KMT2AMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8329377-B2 Imide compound and chemically amplified resist composition containing the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-12-11 US disclosed
US-8329377-B2 Imide compound and chemically amplified resist composition containing the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-12-11 US disclosed
US-20100028807-A1 Imide Compound and Chemically Amplified Resist Composition Containing The Same SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2010-02-04 US disclosed
US-20100028807-A1 Imide Compound and Chemically Amplified Resist Composition Containing The Same SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2010-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100028807-A1 Imide Compound and Chemically Amplified Resist Composition Containing The Same IGF1R, CCNA1, MYC MAOA 1747/4885TNF 3948/4885DRD2 1036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.